Results 71 to 80 of about 4,938,261 (300)

Clinical features and therapeutic outcome of 30 patients diagnosed with primary myelofibrosis at the national center of hematology

مجلة كلية الطب, 2015
Background: Primary myelofibrosis is characterized by clonal expansion of hematopoietic stem cell with a non-reactive clonal proliferation of fibroblasts and bone marrow fibrosis, which occurs at an extramedullary hematopoiesis.
Alaa F. Alwan
doaj   +1 more source

Myeloproliferative neoplasms: a review of diagnostic criteria and clinical aspects [PDF]

, 2010
Chronic myeloproliferative disorders, currently called myeloproliferative neoplasms (MPN), according to the 4th edition of the World Health Organization (WHO) classification are clonal diseases of hematopoietic stem cells, in which there is increased ...
Chauffaille, Maria de Lourdes Lopes Ferrari
core   +1 more source

Drug Repositioning of Pegbing® for Essential Thrombocythemia: Insights from PK/PD Modeling and Extrapolation

Clinical Pharmacology &Therapeutics, EarlyView.
Pegbing® (peginterferon alfa‐2b), a pegylated interferon‐alpha, is approved for the treatment of chronic hepatitis B (CHB) and C. One of its adverse effects is platelet (PLT) suppression. It is currently being repurposed for the treatment of essential thrombocythemia (ET), a rare myeloproliferative disorder characterized by abnormally elevated PLT ...
Weizhe Jian, Yalin Yin, Rong Chen, Junsheng Xue, Jianbo Gu, Zhengfang Du, Ruoyi He, Tianyan Zhou   +7 more
wiley   +1 more source

Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes

Haematologica, 2011
Background The myeloproliferative neoplasms, essential thrombocytosis, polycythemia vera and primary myelofibrosis, share the same acquired genetic lesion, but the concept of JAK2 V617F serving as the sole lesion responsible for these neoplasms is under ...
Brady L. Stein, Donna M. Williams, Christine O’Keefe, Ophelia Rogers, Roxann G. Ingersoll, Jerry L. Spivak, Amit Verma, Jarek P. Maciejewski, Michael A. McDevitt, Alison R. Moliterno   +9 more
doaj   +1 more source

PRIMARY MYELOFIBROSIS

INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY, 2019
 A 55-year-old male was admitted to hospital with chief complaint of abdominal distention since one year before admission, and it became more prominent than before. The physical examination showed splenomegaly with schuffner line S5, and it was confirmed with ultrasonography.
Muhammad Irhamsyah, Darwati Muhadi, Mansyur Arif   +2 more
openaire   +1 more source

Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients

Leukemia, 2018
Current cytogenetic risk stratification in primary myelofibrosis (PMF) is two-tiered: ‘favorable’ and ‘unfavorable’. Recent studies have suggested prognostic heterogeneity within the unfavorable risk category.
A. Tefferi, M. Nicolosi, M. Mudireddy, T. Lasho, N. Gangat, K. Begna, C. Hanson, R. Ketterling, A. Pardanani   +8 more
semanticscholar   +1 more source

JAK2 V617F Analysis in Indonesian Myeloproliferative Neoplasms Patients [PDF]

, 2015
Background : Three subtypes of myeloproliferative neoplasms (MPNs): Polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) showed overlapping phenotype.
Faradz, S. M. (Sultana), Saktini, F. (Fanti), Santosa, S. (Santosa)   +2 more
core   +3 more sources

Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model

Blood Cancer Journal, 2019
Among 1306 patients with primary myelofibrosis (PMF), we sought to identify risk factors that predicted leukemic transformation (LT) in the first 5 years of disease and also over the course of the disease.
Rangit R. Vallapureddy, M. Mudireddy, D. Penna, T. Lasho, C. Finke, C. Hanson, R. Ketterling, K. Begna, N. Gangat, A. Pardanani, A. Tefferi   +10 more
semanticscholar   +1 more source

Philadelphia-negative myeloproliferative neoplasms as disorders marked by cytokine modulation

Hematology, Transfusion and Cell Therapy, 2018
Background: Cytokines are key immune mediators in physiological and disease processes, whose increased levels have been associated with the physiopathology of hematopoietic malignancies, such as myeloproliferative neoplasms.
Maira da Costa Cacemiro, Juçara Gastaldi Cominal, Raquel Tognon, Natalia de Souza Nunes, Belinda Pinto Simões, Lorena Lôbo de Figueiredo-Pontes, Luiz Fernando Bazzo Catto, Fabíola Traina, Elizabeth Xisto Souto, Fabiana Albani Zambuzi, Fabiani Gai Frantz, Fabíola Attié de Castro   +11 more
doaj   +1 more source

Integration of multiparameter flow cytometry score improves prognostic stratification provided by standard models in primary myelofibrosis [PDF]

, 2022
Francesco Mannelli, Sara Bencini, Giacomo Coltro, Giuseppe Gaetano Loscocco, Benedetta Peruzzi, Giada Rotunno, Chiara Maccari, Francesca Gesullo, Miriam Borella, Chiara Paoli, Roberto Caporale, Carmela Mannarelli, Francesco Annunziato, Paola Guglielmelli, Alessandro M. Vannucchi   +14 more
openalex   +1 more source